10 Survival outcomes The primary efficacy analysis (in October 2009) showed a nonsignificant trend toward an OS benefit with decitabine (median 7.7 versus 5.0 months for treatment choice).
← all excerpts
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
1
—
—